Replies to post #82765 on Biotech Values

[iwfal]

VX-770 will be studied in patients bearing the G551D mutation on at least one allele (2 phase III trials), and also in homozygous for the higher prevalence F508del mutation (phase II trial). So VX-770 still has potential beyond G551D patients population.

Missed this (my excuse is it just started its ph ii - while the G551D application is in ph iii). Thanks.